GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Other Income (Expense)

Molecular Partners AG (XSWX:MOLN) Other Income (Expense) : CHF-1.12 Mil (TTM As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Other Income (Expense)?

Molecular Partners AG's other income expense for the Molecular Partners AG's pretax income for the three months ended in Mar. 2024 was CHF3.44 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was CHF-1.12 Mil.


Molecular Partners AG Other Income (Expense) Historical Data

The historical data trend for Molecular Partners AG's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Other Income (Expense) Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.11 -4.51 0.09 0.72 -5.11

Molecular Partners AG Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -1.18 0.87 -4.25 3.44

Molecular Partners AG Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-1.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (XSWX:MOLN) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

By Stock market mentor Stock market mentor 01-08-2023